Monitor execution pace and any subsequent financial reports for fundamental changes. The buyback may provide price support but does not alter the underlying business outlook. Watch for quarterly updates on repurchase activity.
BNTX drugs
BNTX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 8 $85.50entry
- T+1 · 5mo ago +1.17%α +1.46% · $86.50
- T+5 · 5mo ago +6.20%α +4.09% · $90.80
- T+20 · 4mo ago +9.86%α +8.23% · $93.93
- T+60 · 3mo ago +19.23%α +16.18% · $101.95
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioNTech announced the commencement of its previously authorized $1.0 billion share buyback program, effective June 8, 2026, through May 6, 2027. The program allows repurchase of up to 24.9 million ADSs (≈10% of share capital) via an independent credit institution, compliant with 10b-18/10b5-1 rules.
Key Facts
- $1.0 billion share buyback program authorized on May 7, 2026, with buyback period June 8, 2026 to May 6, 2027.
- Up to 24.9 million American Depositary Shares (ADSs) may be repurchased, representing approximately 10% of BioNTech's share capital.
- Buyback will be executed by an independent credit institution in compliance with EU MAR and SEC Rules 10b-18 and 10b5-1.
- Repurchased ADSs may be used for ordinary course obligations and to enhance capital efficiency.
Financial Impact
The $1.0 billion buyback represents approximately 4.5% of BioNTech's $22.1B market cap. Potential EPS accretion if fully executed, but no immediate financial impact.
Risk Factors
- Buyback may not be fully executed due to market conditions or corporate decisions.
- Underlying business fundamentals (e.g., COVID vaccine demand) could deteriorate, offsetting any buyback benefits.
- Regulatory or legal constraints could limit repurchase activity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000041 |
| Document: a991june2026sbbarticle51ma.htm | 0001776985-26-000041 |
| Document: 0001776985-26-000041-index-headers.html | 0001776985-26-000041 |
| Document: 0001776985-26-000041-index.html | 0001776985-26-000041 |
| Document: 0001776985-26-000041.txt | 0001776985-26-000041 |
Track record
38 reports on BNTX
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
- Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
- Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
- Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
- Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
- Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers